It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Genes of the Sprouty family (Spry1-4) restrain signaling by certain receptor tyrosine kinases. Consequently, these genes participate in several developmental processes and function as tumor suppressors in adult life. Despite these important roles, the biology of this family of genes still remains obscure. Here we show that Sprouty proteins are general mediators of cellular senescence. Induction of cellular senescence by several triggers in vitro correlates with upregulation of Sprouty protein levels. More importantly, overexpression of Sprouty genes is sufficient to cause premature cellular senescence, via a conserved N-terminal tyrosine (Tyrosine 53 of Sprouty1). Accordingly, fibroblasts from knockin animals lacking that tyrosine escape replicative senescence. In vivo, heterozygous knockin mice display delayed induction of cellular senescence during cutaneous wound healing and upon chemotherapy-induced cellular senescence. Unlike other functions of this family of genes, induction of cellular senescence appears to be independent of activation of the ERK1/2 pathway. Instead, we show that Sprouty proteins induce cellular senescence upstream of the p38 pathway in these in vitro and in vivo paradigms.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Developmental and Oncogenic Signaling Group, Lleida, Spain (GRID:grid.15043.33) (ISNI:0000 0001 2163 1432); National Institutes of Health, Laboratory of Genetics and Genomics, National Institute on Aging, Baltimore, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165); Consejo Superior de Investigaciones Científicas (CSIC) - Universidad Autónoma de Madrid, Homeostasis de tejidos y órganos program, Centro de Biología Molecular Severo Ochoa, Madrid, Spain (GRID:grid.465524.4)
2 Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Developmental and Oncogenic Signaling Group, Lleida, Spain (GRID:grid.15043.33) (ISNI:0000 0001 2163 1432)
3 Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Developmental and Oncogenic Signaling Group, Lleida, Spain (GRID:grid.15043.33) (ISNI:0000 0001 2163 1432); Investigación, Fundación de Investigación Biomédica de Cádiz, Hospital Universitario Puerta del Mar, Novena Planta, Cádiz, Spain (GRID:grid.411342.1) (ISNI:0000 0004 1771 1175)
4 Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Developmental and Oncogenic Signaling Group, Lleida, Spain (GRID:grid.15043.33) (ISNI:0000 0001 2163 1432); Hospital Universitari Arnau de Vilanova, Lleida, Spain (GRID:grid.411443.7) (ISNI:0000 0004 1765 7340)
5 Gran via De l’Hospitalet, Laboratory of Precision Medicine, Oncobell Program. Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain (GRID:grid.418284.3) (ISNI:0000 0004 0427 2257)